

References

S-152

1. InterQual® Level of Care Criteria 2019, Acute Care Adult, McKesson Health Solutions, LLC.
2. Messé S, Gronseth G, Kent D, Kizer G, et al. Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter): *Neurol* 2016;87(8): 815-821.
3. Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. *N Engl J Med*. 2017;377:1022-1032.
4. Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. *N Engl J Med*. 2017;377(11):1033-1042.
5. Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. *N Engl J Med*. 2017;377:1011-1021.
6. Kent DM, Dahabreh IJ, Ruthazer R, et al. Device closure of patent foramen ovale after stroke: Pooled analysis of completed randomized trials. *Am J Cardio*. 2016;67(8):907-917.
7. S. Food and Drug Administration. Summary of safety and effectiveness data. Gore cardioform septal occluder. March 30, 2018. https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050006s060b.pdf. Accessed June 03, 2021.
8. Food and Drug Administration (FDA). Summary of safety and effectiveness data (SSED): Patent foramen ovale (PFO) occluder (PMA P120021). 2016; https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120021B.pdf. Accessed June 03, 2021.
9. Rogers T, Slack M, Waksman R. Overview of the 2016 US Food and Drug Administration circulatory system devices panel meeting on the amplatzer patent foramen ovale occluder. *Am J Cardiol*. 2017; 119(1):153-155.

10. Shah R, Nayyar M, Jovin IS, et al. Device closure versus medical therapy alone for patent foramen ovale in patients with cryptogenic stroke: A systematic review and meta-analysis. *Ann Intern Med.* 2018;168(5):335-342.
11. De Rosa S, Sievert H, Sabatino J, et al. Percutaneous closure versus medical treatment in stroke patients with patent foramen ovale: A systematic review and meta-analysis. *Ann Intern Med.* 2018;168(5):343-350.
12. S. Food and Drug Administration. Summary of safety and effectiveness data. Gore Cardioform Septal Occluder. March 30, 2018. https://www.accessdata.fda.gov/cdrh_docs/pdf5/P050006s060b.pdf. Accessed June 03, 2021
13. Food and Drug Administration (FDA). Summary of safety and effectiveness data (SSED): Patent Foramen Ovale (PFO) occluder (PMA P120021). 2016; https://www.accessdata.fda.gov/cdrh_docs/pdf12/P120021B.pdf. Accessed June 03, 2021.
14. Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and high-risk patent foramen ovale: The defense-PFO trial. *J Am Coll Cardiol.* 2018;71(20):2335-2342.
15. Sondergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. *N Engl J Med.* 2017;377(11):1033-1042.
16. Alushi B, Lauten A, Cassese S, et al. Patent foramen ovale closure versus medical therapy for prevention of recurrent cryptogenic embolism: Updated meta-analysis of randomized clinical trials. *Clin Res Cardiol.* 2018;107(9):788-798.
17. Rigatelli G, Pedon L, Zecchel R, et al. Long-term outcomes and complications of intracardiac echocardiography-assisted patent foramen ovale closure in 1,000 consecutive patients. *J Interv Cardiol.* 2016; 29(5):530-538.
18. Wintzer-Wehekind J, Alperi A, Houde C, et al. Long-term follow-up after closure of patent foramen ovale in patients with cryptogenic embolism. *J Am Coll Cardiol.* 2019;73(3):278-287.

19. Mattle HP, Evers S, Hildick-Smith D, et al. Percutaneous closure of patent foramen ovale in migraine with aura, a randomized controlled trial. *Eur Heart J*. 2016;37(26):2029-36.
20. Tobis JM, Charles A, Silberstein SD, et al. Percutaneous closure of patent foramen ovale in patients with migraine: The premium trial. *J Am Coll Cardiol*. 2017;70(22):2766-2774
21. Snijder RJ, Luermans JG, de Heij AH, et al. Patent foramen ovale with atrial septal aneurysm is strongly associated with migraine with aura: A large observational study. *J Am Heart Assoc*. 2016;5(12). 45
22. Jalal Z, Hascoet S, Gronier C, et al. Long-term outcomes after percutaneous closure of ostium secundum atrial septal defect in the young: A nationwide cohort study. *JACC Cardiovasc Interv*. 2018;11(8):795-804.
23. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2019;73(12):e81-e192.